Summary
Vertex Pharmaceuticals Inc. (VRTX) held its 2015 annual meeting of shareholders on June 4, 2015, where several key corporate actions were approved. Most notably, shareholders approved an amendment to the company's Restated Articles of Organization to increase the authorized number of common stock shares from 300 million to 500 million. This significant increase in authorized shares provides Vertex with greater financial flexibility for future strategic initiatives, such as potential acquisitions, stock-based compensation, or other corporate financing needs. Additionally, shareholders approved an amendment and restatement of the 2013 Stock and Option Plan, authorizing an additional 7.8 million shares for issuance under this plan. The company also saw the election of three directors to its board: Sangeeta N. Bhatia, Jeffrey M. Leiden, and Bruce I. Sachs, all approved by a substantial majority of votes. While most proposals passed with strong shareholder support, an advisory vote on executive compensation did not receive majority approval, and a shareholder proposal requesting a report on specialty drug prices was also not approved.
Key Highlights
- 1Shareholders approved an increase in authorized common stock from 300 million to 500 million shares, providing significant financial and strategic flexibility.
- 2An amendment and restatement of the 2013 Stock and Option Plan was approved, authorizing an additional 7.8 million shares for issuance.
- 3Sangeeta N. Bhatia, Jeffrey M. Leiden, and Bruce I. Sachs were elected to the Board of Directors until the 2018 annual meeting.
- 4The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2015 was ratified.
- 5Shareholders approved a shareholder proposal regarding a proxy access by-law.
- 6An advisory vote on the compensation program for named executive officers did not receive majority shareholder approval.
- 7A shareholder proposal requesting a report on specialty drug prices was not approved.